In this study, we found that metformin could act as a senostatic drug to modulate the profiles of the SASP elicited by a CDK4/6 inhibitor and thus enhance the anticancer effect on HNSCC. This evidence concerns the gene CDK4 and head and neck squamous cell carcinoma.